We’re moving the GATK website, docs and forum to a new platform. Read the full story and breakdown of key changes on this blog.
If you happen to see a question you know the answer to, please do chime in and help your fellow community members. We encourage our fourm members to be more involved, jump in and help out your fellow researchers with their questions. GATK forum is a community forum and helping each other with using GATK tools and research is the cornerstone of our success as a genomics research community.We appreciate your help!
Test-drive the GATK tools and Best Practices pipelines on Terra
Check out this blog post to learn how you can get started with GATK and try out the pipelines in preconfigured workspaces (with a user-friendly interface!) without having to install anything.
GATK Workflow for Cancer
I am new to Bioinformatics, and would like some advice on changes to the GATK workflow for cancer. I was told that the cancer workflow is different, and see that several different tools are available.
I have Exome data from tumor and normal. I have aligned them, and have BAM files for each sample. I am interested in identifying somatic variants.
The current workflow as I understand it is:
-(Non-GATK) Picard Mark Duplicates or Samtools roundup
-Indel Realignment (Realigner TargetCreator + Indel Realigner)
-Base Quality Score Reacalibration (Base Recalibrator + PrintReads)
-Annotation using Oncotator (?)
-MuTect (identify somatic mutations)
My questions are:
1. Is the above workflow reasonable/correct for what I'm trying to do?
2. Is there any difference running samples one pair at a time, or running them all together? (I have 57 pairs. Should I do 57 runs of normal-tumor pairs, or 1 run of all 57 pairs?)